Scientists found a virus-like living entity in human bodies named "obelisks" - small loops of RNA, each a thousand genetic ...

Fintel reports that on October 27, 2025, Needham downgraded their outlook for Avidity Biosciences (NasdaqGM:RNA) from Buy to ...

Fintel reports that on October 27, 2025, Bernstein downgraded their outlook for Avidity Biosciences (NasdaqGM:RNA) from ...

A research team at the Max Planck Institute for Chemical Ecology has successfully combined single-cell RNA sequencing ...

Avidity Biosciences (RNA) to be acquired by Novartis in a $12 billion cash deal. H.C. Wainwright downgrades to Neutral.

Novartis is buying Avidity Biosciences for $12 billion, picking up RNA-based medicines for neuromuscular diseases as it seeks ...

Novartis is buying Avidity Biosciences in an all-cash deal valued at $12 billion to access Avidity's experimental treatments for neuromuscular diseases.

Novartis is poised to make one of its largest takeover deals in its history after agreeing to buy RNA specialist Avidity ...

Novartis announces agreement to buy Avidity Biosciences for $12 billion. Here's why NVS is paying such a hefty premium for ...

Avidity stock surges on $12B Novartis deal. Bessent unveils Fed chair finalists before year-end decision. HSBC faces $1.1B ...

The interior of a cell is packed with proteins and nucleic acids, such as RNA, all of which need to perform specific ...

Avidity Biosciences (RNA) shares surged as much as 45% in premarket trading on Monday after Novartis (NVS) agreed to buy the biotechnology company in a deal valued at $12 billion.